Katharina Schütz

11PUBLICATIONS
32CO-AUTHORS
Fluid-structure interaction and aeroacousticsInfant and child healthMajor global burdens of diseaseCancer therapy (excl. chemotherapy and radiation therapy)Adolescent health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Mar 18, 2026
Long-term impact of elexacaftor/tezacaftor/ivacaftor on small and large airways in people with cystic fibrosis aged ≥6 years: 24-month real-world evidence from the German Cystic Fibrosis Registry.

Stefanie Dillenhöfer, Katharina Schütz, Manuel Burkhart

|Sep 18, 2025
Reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor correlates with lung function improvement in cystic fibrosis.

Olga Halle, Simon Y Graeber, Julia Kontsendorn

|Aug 22, 2025
Rigid and Flexible Bronchoscopy for Foreign Body Removal in Children: Complications, Risk Factors and Anesthetic Management.

Oliver Keil, Yehor Huzhva, Vanessa Rigterink

|Aug 05, 2025
Cystic fibrosis transmembrane conductance regulator therapy with elexacaftor/tezacaftor/ivacaftor reduces detection of hallmark cystic fibrosis pathogens in Europe: progress made but no time to slow down.

Katharina Schütz, Sophia T Pallenberg, Ilona Rosenboom

|Dec 10, 2024
CFTR Modulator Treatment in Children<12 Years of Age - Status Quo and Challenges.

Dominik Funken, Katharina Schütz, Anna-Maria Dittrich

|Jun 20, 2024
Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del alleles.

Mirjam Stahl, Martha Dohna, Simon Y Graeber

Pageof 2

Frequent Collaborators

5 joint publications

Anna-Maria Dittrich

3 joint publications

Mirjam Stahl

3 joint publications

Marcus A Mall

2 joint publications

Jobst Röhmel